49 results on '"Schmitt‐Egenolf, Marcus"'
Search Results
2. The Influence of Socioeconomic Factors on Access to Biologics in Psoriasis
3. Prolonged Sick Leave Before and After Diagnosis of Generalized Pustular Psoriasis: A Swedish Population-based Register Study
4. Mortality in generalized pustular psoriasis: A population-based national register study
5. Patient reported experiences of Swedish patients being investigated for cancer during the Covid-19 pandemic
6. The Disruptive Force of Real-World Evidence
7. Comorbidities in palmoplantar pustulosis: a Swedish population-based register study
8. Psoriasis Involving Special Areas is Associated with Worse Quality of Life, Depression, and Limitations in the Ability to Participate in Social Roles and Activities
9. Comorbidities in patients with generalized pustular psoriasis: a nationwide population-based register study
10. Economic Burden of Palmoplantar Pustulosis in Sweden: A Population-based Register Study
11. The Use of IL-17 and IL-23 Inhibitors in Swedish Clinical Practice: A Register-Based Analysis
12. Patient Registries for Safetyness
13. Economic Burden of Generalized Pustular Psoriasis in Sweden: A Population-Based Register Study
14. Severity of psoriasis: time to disentangle severity from symptom control
15. Prevalence and incidence of generalized pustular psoriasis in Sweden: a population‐based register study*
16. Perception of information to Swedish melanoma patients in routine clinical practice – a cross-sectional survey
17. Diverse research designs are needed for population health: Lessons from Maslow
18. Long-Term Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus and Pimecrolimus: Final Results from the Extension of the Cohort Study Protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE)
19. Drug Persistence of Biologic Treatments in Psoriasis: A Swedish National Population Study
20. Paediatric infections in the first 3 years of life after maternal anti‐TNF treatment during pregnancy
21. Association of Skin Psoriasis and Somatic Comorbidity With the Development of Psychiatric Illness in a Nationwide Swedish Study
22. Anti‐TNF treatment during pregnancy and birth outcomes: A population‐based study from Denmark, Finland, and Sweden
23. Immunsystem Haut
24. How is disease severity associated with quality of life in psoriasis patients? Evidence from a longitudinal population-based study in Sweden
25. Severity of Psoriasis Differs Between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients
26. Regional Differences in the Prescription of Biologics for Psoriasis in Sweden: A Register-Based Study of 4168 Patients
27. Periodontal Ehlers-Danlos Syndrome Is Caused by Mutations in C1R and C1S , which Encode Subcomponents C1r and C1s of Complement
28. Healthcare Provider Type and Switch to Biologics in Psoriasis: Evidence from Real-World Practice
29. Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden
30. News and Notices
31. Real-World Outcome Analysis of Continuously and Intermittently Treated Patients with Moderate to Severe Psoriasis after Switching to a Biologic Agent
32. EDAR-induced hypohidrotic ectodermal dysplasia: a clinical study on signs and symptoms in individuals with a heterozygous c.1072C > T mutation
33. Health-Care Delay in Malignant Melanoma: Various Pathways to Diagnosis and Treatment
34. The Higher Proportion of Men with Psoriasis Treated with Biologics May Be Explained by More Severe Disease in Men
35. Coping styles in decision-making among men and women diagnosed with malignant melanoma
36. Melbourne Decision Making Questionnaire--Swedish Version
37. Switch to Biological Agent in Psoriasis Significantly Improved Clinical and Patient-Reported Outcomes in Real-World Practice
38. Malignant melanoma: gender patterns in care seeking for suspect marks
39. Patients’ decision making in seeking care for suspected malignant melanoma
40. Switching Biologicals: Switching TNFα Antagonists in Psoriasis Treatment
41. PsoReg – The Swedish Registry for Systemic Psoriasis Treatment
42. EDAR mutation in autosomal dominant hypohidrotic ectodermal dysplasia in two Swedish families
43. Psoriasis Therapy in Real Life: The Need for Registries
44. Genomewide Scan in German Families Reveals Evidence for a Novel Psoriasis-Susceptibility Locus on Chromosome 19p13
45. Survival, Maturation, and Function of CD11c− and CD11c+ Peripheral Blood Dendritic Cells Are Differentially Regulated by Cytokines
46. Promoter Polymorphism at –238 of the Tumor Necrosis Factor Alpha Gene is Not Associated with Early Onset Psoriasis when Tested by the Transmission Disequilibrium Test
47. Familial Juvenile Onset Psoriasis Is Associated with the Human Leukocyte Antigen (HLA) Class I side of the Extended Haplotype Cw6-B57-DRB1*0701-DQA1*0201-DQB1*0303: A Population- And Family-Based Study
48. Analysis of TAP2 and HLA-DP gene polymorphism in Psoriasis
49. Oligonucleotide Typing Reveals Association of Type I Psoriasis with the HLA-DRB1*0701/2, -DQA* 0201, -DQB1*0303 Extended Haplotype
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.